2017 Press Releases

2017 | 2016 | 2015 | 2014 | 2013 | 2012

AMAG Pharmaceuticals to Present at the Deutsche Bank Health Care Conference

WALTHAM, Mass., April 26, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that management will participate in a fireside chat at the 42nd Annual Deutsche Bank Health Care Conference on Wednesday, May 3, 2017 at 2:50 p.m. ET. A live audio webcast will be accessi... More > 

AMAG Pharmaceuticals Appoints Arpad Simon, M.D. as Vice President of Pharmacovigilance

WALTHAM, Mass., April 25, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced the appointment of Arpad Simon, M.D., to the role of vice president of pharmacovigilance. Dr. Simon has worked in the pharmaceutical industry for more than 20 years with extensive operationa... More > 

AMAG Pharmaceuticals to Host First Quarter 2017 Financial Results Conference Call and Webcast on Tuesday, May 2, 2017 at 8:00 a.m. ET

WALTHAM, Mass., April 19, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that its first quarter 2017 financial results will be released on Tuesday, May 2, 2017 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m.... More > 

AMAG Submits Supplemental New Drug Application to FDA for Makena® (Hydroxyprogesterone Caproate Injection) Auto-Injector for Subcutaneous Use

FDA Decision Anticipated on sNDA filing in the Fourth Quarter 2017 WALTHAM, Mass., April 17, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) announced today that it has submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for the Ma... More > 

AMAG Pharmaceuticals Announces Closing of Exclusive Licensing Agreement With Endoceutics for U.S. Rights to Intrarosa™ (Prasterone)

Anticipated U.S. launch in mid-2017 WALTHAM, Mass., April 04, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) announced today the closing of the licensing agreement with Endoceutics, Inc. for the U.S. commercial rights to IntrarosaTM (prasterone). Intrarosa is the only FDA-appro... More > 

AMAG Pharmaceuticals to Present at the Needham Healthcare Conference

WALTHAM, Mass., March 28, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that management will present at the 16th Annual Needham Healthcare Conference on Tuesday, April 4, 2017 at 4:20 p.m. ET. A live audio webcast will be accessible through the Investors sect... More > 

AMAG Announces Management Changes and New Commercial Appointments

WALTHAM, Mass., March 06, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced changes to the company’s executive and commercial leadership teams, including that Frank Thomas, president and chief operating officer, intends to transition out of the organization on April... More > 

AMAG Pharmaceuticals to Present at Upcoming Investor Conferences

WALTHAM, Mass., March 01, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will participate in the following investor conferences: Cowen and Company Annual Health Care Conference  Monday, March 6, 2017 at 2:40 p.m. ET   Location: Bo... More > 

AMAG and Palatin Announce Rekynda™ Data Presentations at the International Society for the Study of Women’s Sexual Health Annual Meeting

Both Phase 3 RECONNECT studies met co-primary endpoints and demonstrated significant improvement in key symptoms of hypoactive sexual desire disorder ... More > 

AMAG Reports Fourth Quarter and Full Year 2016 Financial Results

2016 GAAP revenue increased 27% over 2015 Achieved record quarterly and annual net sales for Makena® and Feraheme® Conference call scheduled for 8:00 a.m. ET today WALTHAM, Mass., Feb. 14, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today reported unaudited consolidated f... More > 

AMAG and Endoceutics Enter Into an Exclusive U.S. License Agreement for Intrarosa™ (Prasterone)

Recently approved first-of-its-kind, non-estrogen prescription therapy for a common symptom of menopause Conference call sch... More > 

AMAG Pharmaceuticals to Present at Upcoming Investor Conference

WALTHAM, Mass., Feb. 09, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that management will participate in an analyst-led fireside chat at the Leerink Partners Global Healthcare Conference on Thursday, February 16, 2017 at 2:00 p.m. EST. A live audio webcast ... More > 

AMAG Pharmaceuticals to Host Fourth Quarter and Full Year 2016 Financial Results Conference Call and Webcast on Tuesday, February 14, 2017 at 8:00 a.m. ET

WALTHAM, Mass., Feb. 07, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that it will report financial results for the fourth quarter and year ended December 31, 2016 on Tuesday, February 14, 2017 before the U.S. financial markets open. Management will host a conf... More > 

AMAG Pharmaceuticals Announces Closing of Exclusive Licensing Agreement for North American Rights to Rekynda™ (bremelanotide)

Anticipated new drug application (NDA) filing in early 2018 WALTHAM, Mass., Feb. 03, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) announced today the closing of the licensing agreement with Palatin Technologies, Inc. for exclusive North American commercial rights to RekyndaTM... More > 

AMAG Pharmaceuticals Announces Positive Topline Results from Definitive Pharmacokinetic Study for Makena Subcutaneous Administration

Supplemental new drug application on track for second quarter 2017 filing WALTHAM, Mass., Feb. 02, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced results from its definitive pharmacokinetic (PK) study designed to demonstrate comparable bioavailability of the sub... More > 

AMAG Pharmaceuticals Provides Financial and Business Update

2016 total revenue increased 45 percent Provides update on Makena® next-generation program Anticipates 2017 GAAP revenue of $620-$670 million, including Makena net sales of $410-$440 million WALTHAM, Mass., Jan. 09, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today provi... More > 

AMAG Pharmaceuticals and Palatin Technologies Enter Into Exclusive Licensing Agreement for North American Rights to Rekynda™ (bremelanotide), a Potential Treatment for a Common Female Sexual Disorder

Two Phase 3 trials completed for Rekynda; co-primary endpoints met Will address underserved medical condition with significant untapped market potential Broadens AMAG’s presence in women’s health and leverages AMAG’s commercial capabilities and customer relationships WALTHAM, Mass. and CRANBURY... More > 

AMAG Pharmaceuticals to Present at the 35th Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan. 03, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that William Heiden, chief executive officer, will present at the 35th Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2017 at 11:30 a.m. Pacific Time (2:30 p.m. Eastern Time... More >